Steinert H C
Klinik und Poliklinik für Nuklearmedizin, Universitätsspital Zürich, Schweiz.
Radiologe. 2004 Nov;44(11):1060-7. doi: 10.1007/s00117-004-1121-x.
First results of PET/CT in Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) are reported.
From March 2001 to August 2004 822 PET/CT were performed at our clinic in lymphoma patients for primary staging, restaging after therapy, and diagnosis of recurrence. For coregistration non contrast-enhanced low-dose CT were used.
Due to the exact anatomic localization of (18)F-FDG accumulating lesions equivocal or false positive PET findings are avoided. In comparison to contrast enhanced CT, PET/CT has a higher sensitivity and specificity in patients with HD and aggressive NHL. Integration of PET/CT in treatment planning of radiation therapy optimizes the field volume.
Even in the initial phase of clinical evaluation, PET/CT has proven useful in staging and restaging of lymphoma. The exact anatomic localization of the PET findings is essential for a precise report, for treatment planning of radiation therapy, and for planning surgical biopsy.
报告正电子发射断层显像/计算机断层扫描（PET/CT）在霍奇金淋巴瘤（HD）和侵袭性非霍奇金淋巴瘤（NHL）中的初步结果。
2001年3月至2004年8月期间，我们诊所对淋巴瘤患者进行了822次PET/CT检查，用于初始分期、治疗后再分期以及复发诊断。为进行图像配准，使用了非增强低剂量CT。
由于（18）F-氟代脱氧葡萄糖（FDG）摄取病变的精确解剖定位，避免了PET检查结果模棱两可或出现假阳性。与增强CT相比，PET/CT在HD和侵袭性NHL患者中具有更高的敏感性和特异性。将PET/CT整合到放射治疗计划中可优化照射野范围。
即使在临床评估的初始阶段，PET/CT已被证明在淋巴瘤分期和再分期中有用。PET检查结果的精确解剖定位对于准确报告、放射治疗计划以及手术活检计划至关重要。
